Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 11, 2009, Pages 1180-1189

  Rode, Line ^a   Langhoff Roos, Jens ^a   Andersson, Charlotte ^b   Dinesen, Jakob ^c   Hammerum, Mette Schou ^d   Mohapeloa, Hanne ^e   Tabor, Ann ^a,f  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c HERNING HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

High risk pregnancies; Preterm birth; Progesterone; Singletons

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR;

BRAIN HEMORRHAGE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; EMBASE; GESTATION PERIOD; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; MEDLINE; META ANALYSIS; METHODOLOGY; PERINATAL MORTALITY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; UTERINE CERVIX;

FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70449565668     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903280982     Document Type: Review

References (49)

1. Larroque B, Breart G, Kaminski M, Dehan M, Andre M, Burguet A, et al. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed. 2004;89:F139-44.
2. Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V, Larroque B, et al. Neonatal and 5-year outcomes after birth at 30-34 weeks of gestation. Obstet Gynecol. 2007;110:72-80.
3. Allin M, Rooney M, Griffiths T, Cuddy M, Wyatt J, Rifkin L, et al. Neurological abnormalities in young adults born preterm. J Neurol Neurosurg Psychiatry. 2006;77:495-499
4. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. Cognitive and behavioral outcomes of school-aged children who were born preterm: A meta-analysis. JAMA. 2002; 288:728-737
5. Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. BMJ. 2006;332:937-939 (Pubitemid 44365549)
6. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, et al. The preterm parturition syndrome. BJOG. 2006;113:17-42.
7. Smith R, Van HD, Hirst J, Zakar T, Read M, Chan EC, et al. Pathological interactions with the timing of birth and uterine activation. Aust N Z J Obstet Gynaecol. 2007;47:430-437
8. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990; 97:149-154
9. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: A meta-analysis of randomized controlled trials. Obstet Gynecol. 2005;105:273-279 (Pubitemid 40229441)
10. Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: A systematic review. Obstet Gynecol. 2008;112:127-134
11. Dodd JM, Crowther CA, Cincotta R, Flenady V, Robinson JS. Progesterone supplementation for preventing preterm birth: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2005;84:526-533
12. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: A systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2006; 194:1234-1242
13. Coomarasamy A, Thangaratinam S, Gee H, Khan KS. Progesterone for the prevention of preterm birth: A critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol. 2006;129:111-118
14. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev. 2006;CD004947.
15. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385
16. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebocontrolled double-blind study. Am J Obstet Gynecol. 2003; 188:419-424
17. Astle S, Slater DM, Thornton S. The involvement of progesterone in the onset of human labour. Eur J Obstet Gynecol Reprod Biol. 2003;108:177-181
18. Patel FA CJ. Prostaglandins and uterine activity. In: Smith R (ed). The endocrinology of parturition. Basic science and clinical application. Frontiers of hormone research. Basel: Karger, 2001.
19. Smith R. Parturition. N Engl J Med. 2007;356:271-283
20. Word RA, Li XH, Hnat M, Carrick K. Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts. Semin Reprod Med. 2007;25:69-79.
21. Lin TJ, Billiar RB, Little B. Metabolic clearance of progesterone in the menstrual cycle. J Clin Endocrinol Metab. 1972; 35:879-886
22. Tulchinsky D, Okada DM. Hormones in human pregnancy. IV. Plasma progesterone. Am J Obstet Gynecol. 1975; 121:293-299
23. Papiernik-Berkhauer E. Étude en double aveugle d'un médicament prévenant la survenue prématurée de l'accouchement chez les femmes 'à risque élevé' d'accouchement prématuré. Edition Schering, Série IV. 1970;3:65-68.
24. Loudon JA, Elliott CL, Hills F, Bennett PR. Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod. 2003;69:331-337
25. Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391-397
26. Christian MS, Brent RL, Calda P. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in highrisk pregnancies: A review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med. 2007;20:89-112.
27. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985; 65:775-780
28. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. Fertil Steril. 1994; 62:485-490
29. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999; 44:141-147
30. Benifla JL, Dumont M, Levardon M, Foucher E, Cadiot G, Crenn-Hebert C, et al. Effects of micronized natural progesterone on the liver during the third trimester of pregnancy. Contracept Fertil Sex. 1997;25:165-169
31. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 1986; 154:525-529
32. Noblot G, Audra P, Dargent D, Faguer B, Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 1991;40:203-209
33. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687-696
34. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462-469
35. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: A secondary analysis from a randomized, double-blind, placebocontrolled trial. Ultrasound Obstet Gynecol. 2007; 30:697-705.
36. Rai P, Rajaram S, Goel N, Ayalur GR, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104:40-43
37. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675-680
38. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: Effects of 17-alpha- hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:453-454
39. American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 419, October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol. 2008;112:963-965
40. Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary- Goldman J, Rhea DJ, Stanziano GJ, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care. 2007;30:2277-2280
41. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005;193:1127-1131
42. Jayasooriya GS, Lamont RF. The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth. Expert Opin Pharmacother. 2009; 10:1007-1016
43. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008;CD003511.
44. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol. 2007;110:865-872
45. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstet Gynecol. 1995;85:141-149
46. Reinisch JM, Ziemba-Davis M, Sanders SA. Hormonal contributions to sexually dimorphic behavioral development in humans. Psychoneuroendocrinology. 1991;16:213-278
47. Berghella V, Odibo AO, To MS, Rust OA, Althuisius SM. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106:181-189
48. Bailit JL, Votruba ME. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:219.e1-7
49. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17alphahydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. Obstet Gynecol. 2006; 108:492-499